Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.

Krawitt EL, Gordon SR, Grace ND, Ashikaga T, Ray MA, Palmer M, Yarze JC, Moskowitz S; New York New England Study Team..

Am J Gastroenterol. 2006 Jun;101(6):1268-73.

PMID:
16771948
2.

Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.

Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM, Bringman D, Farmer D, Levinthal G, Mullen KD, Carey WD, Tavill AS, Ferguson R, Gramlich T.

Dig Dis Sci. 2005 May;50(5):970-5.

PMID:
15906777
3.
5.
6.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK.

Lancet. 2001 Sep 22;358(9286):958-65.

PMID:
11583749
7.

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS.

J Viral Hepat. 2005 May;12(3):283-91.

PMID:
15850469
8.

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.

Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, Falco V, Quer J, Ocaña I, Ruiz I, Buti M, Pahissa A, Esteban R, Guardia J.

J Viral Hepat. 2007 Apr;14(4):228-38.

PMID:
17381714
9.

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R, Al-Nakib B.

Am J Gastroenterol. 2004 Sep;99(9):1733-7.

PMID:
15330911
10.

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C; French multicenter study group..

J Viral Hepat. 2006 Dec;13(12):811-20.

PMID:
17109680
11.

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK; International Hepatitis Interventional Therapy Group..

Gastroenterology. 2002 Oct;123(4):1061-9.

PMID:
12360468
12.

Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection.

Horsmans Y, Colle I, Van Vlierberghe H, Langlet P, Adler M, Bourgeois N, Brenard R, Michielsen P, Goossens A, Bruckers L; Belgian Assocation for the Study of the Liver..

Acta Gastroenterol Belg. 2008 Jul-Sep;71(3):293-7.

PMID:
19198574
13.
14.

Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.

Mathew A, Peiffer LP, Rhoades K, McGarrity T.

Dig Dis Sci. 2006 Nov;51(11):1956-61.

PMID:
17004124
15.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.

PMID:
12827916
16.

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.

Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdés A, Martell M, Esteban R.

Hepatology. 2002 Apr;35(4):930-6.

PMID:
11915041
17.

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group..

Ann Intern Med. 2004 Mar 2;140(5):346-55.

PMID:
14996676
18.

Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.

Benetti G, Borzio M, Ramella G, Bellati G, Fargion S, Colombo A, Croce G, Iamoletti C, Balzola F, Rizzetto M; GEL (Gruppo Epatologico Lombardo)..

Intern Emerg Med. 2006;1(2):113-8.

PMID:
17111783
19.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

Am J Gastroenterol. 2004 Aug;99(8):1490-6.

PMID:
15307866
20.

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.

Meyer-Wyss B, Rich P, Egger H, Helbling B, Müllhaupt B, Rammert C, Gonvers JJ, Oneta C, Criblez D, Rossi L, Borovicka J, Meyenberger C, Arn M, Renner EL; Swiss Association for the Study of the Liver (SASL)..

J Viral Hepat. 2006 Jul;13(7):457-65.

PMID:
16792539

Supplemental Content

Support Center